There was also a significant difference in the period until tumor enlargement, indicating that the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI is a promising imaging biomarker to predict the therapeutic effect of anti-PD-1/PD-L1 monotherapy [83]. This evidence concerns the gene CD274 and neoplasm.